Confirmation of Family Cancer History Reported in a Population-Based Survey

Phuong, L.; Garceau, Anne O.; Graubard, Barry I.; Dunn, Marsha; McNeel, Timothy S.; Gonsalves, Lou; Gail, Mitchell H.; Greene, Mark H.; Willis, Gordon; Wideroff, Louise

doi:10.1093/jnci/djr114

Cited by 91 publications

(89 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For first-degree relatives, previous studies have however found reported ovarian cancer history to be reasonably accurate (83.3% probability of agreement between reported ovarian cancer status in first-degree relatives and status according to reference standard, 95% CI 72.8 to 93.8) 23 24. A further drawback of our study is the lack of information on tumour subtypes in relatives.…”

Section: Discussionmentioning

confidence: 64%

Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 64%

Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants

et al. 2013

View full text Add to dashboard Cite

show abstract

“…With respect to family history, sharing cancer information within families and the accuracy of reporting depends on multiple factors such as geographical distance, familial culture of communication, degree of relatedness, gender, and knowledge about cancer (34)(35)(36). Reporting of first-degree relatives and breast cancer is generally more accurate than reporting of second-degree relatives and other cancers (37)(38)(39), with ovarian cancer often underreported (38,39). Because the USPSTF risk classification depends on the number and relatedness of affected relatives, an underreporting of ovarian cancer may have led to an underestimation of the number of women at high-risk.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Healthcare Actions of Women in a Large Health System with a Family History Meeting the 2005 USPSTF Recommendation for BRCA Genetic Counseling Referral

Bellcross

Leadbetter

Alford

et al. 2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: In 2005, the United States Preventive Services Task Force (USPSTF) released guidelines which outlined specific family history patterns associated with an increased risk for BRCA1/2 mutations, and recommended at-risk individuals be referred for genetic counseling and evaluation for BRCA testing. The purpose of this study was to assess the prevalence of individuals with a USPSTF increased-risk family history pattern, the frequency with which specific patterns were met, and resulting healthcare actions among women from the Henry Ford Health System.Methods: As part of a study evaluating ovarian cancer risk perception and screening, 2,524 randomly selected participants completed a detailed interview (response rate 76%) from an initial eligible cohort of 16,720 women.Results: Approximately 6% of participants had a family history fulfilling one or more of the USPSTF patterns. Although 90% of these women had shared their family history with their provider, less than 20% had been referred for genetic counseling and only 8% had undergone genetic testing. Caucasian women with higher income and education levels were more likely to receive referrals. Among the 95 participants in the total study cohort who reported BRCA testing, 78% did not have a family history that met one of the USPSTF patterns.Conclusions: These results suggest a higher prevalence of women with an increased-risk family history than originally predicted by the USPSTF, and lack of provider recognition and referral for genetic services.Impact: Improvements in healthcare infrastructure and clinician education will be required to realize population level benefits from BRCA genetic counseling and testing. Cancer Epidemiol Biomarkers Prev; 22(4); 728-35. Ó2013 AACR.

show abstract

“…Breast cancer analyses will also include previous benign breast disease (fibrocystic disease, intraductal papilloma or fibroadenoma) 49. The results will also be adjusted for family history of cancer50 (this will vary according to the cancer under consideration) if recorded 6 months before the index date. This is to reduce family recall bias as cases are more likely to report a family history of cancer around the time of diagnosis 51…”

Section: Methods and Analysismentioning

confidence: 99%

Exposure to bisphosphonates and risk of cancer: a protocol for nested case–control studies using the QResearch primary care database

2012

View full text Add to dashboard Cite

IntroductionBisphosphonates are becoming a common treatment for osteoporosis particularly after discovery of the association between hormone replacement therapy and increased risk of breast cancer. As osteoporosis develops with age, treatment is a long-term intervention. Randomised control trials typically have limited follow-up times, which restricts investigation of the effects of the drugs on risk of primary cancers. A few observational studies have demonstrated a reduced risk of breast cancer and possibly of endometrial cancer in bisphosphonate users. Two epidemiological studies have studied the effect of the drugs on oesophageal cancer but did not reach any definite conclusions. So far, no effects on colorectal and stomach cancer have been shown. This study will investigate the association of bisphosphonates with risks of the 10 most common primary cancers.Methods and analysisA series of nested case–control studies will be based on the general population using records from 660 UK general practices within the QResearch Database. Cases will be patients with primary cancers diagnosed between 1996 and 2011. Each case will be matched by age, sex, practice and calendar year to five controls, who are alive and registered with the practice at the time of diagnosis of the case. Exposure to bisphosphonates will be defined as at least one prescription during the study period. For the most common cancers with substantial numbers of observations, the effect of the duration of the treatment and different types of bisphosphonates will be studied. Conditional logistic regression will be applied to produce ORs adjusted for smoking status, socioeconomic status, ethnicity, cancer-specific co-morbidities and use of other medications.

show abstract

Confirmation of Family Cancer History Reported in a Population-Based Survey

Cited by 91 publications

References 28 publications

Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants

Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants

Prevalence and Healthcare Actions of Women in a Large Health System with a Family History Meeting the 2005 USPSTF Recommendation for BRCA Genetic Counseling Referral

Exposure to bisphosphonates and risk of cancer: a protocol for nested case–control studies using the QResearch primary care database

Contact Info

Product

Resources

About